Zomedica Corp (ZOM) concluded trading on Wednesday at a closing price of $0.11, with 5.14 million shares of worth about $0.57 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -22.34% during that period and on Wednesday the price saw a loss of about -4.33%. Currently the company’s common shares owned by public are about 979.95M shares, out of which, 962.66M shares are available for trading.
Stock saw a price change of -11.89% in past 5 days and over the past one month there was a price change of -13.61%. Year-to-date (YTD), ZOM shares are showing a performance of -11.67% which decreased to -14.86% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.11 but also hit the highest price of $0.20 during that period. The average intraday trading volume for Zomedica Corp shares is 5.47 million. The stock is currently trading -11.35% below its 20-day simple moving average (SMA20), while that difference is down -14.38% for SMA50 and it goes to -22.00% lower than SMA200.
Zomedica Corp (AMEX: ZOM) currently have 979.95M outstanding shares and institutions hold larger chunk of about 9.35% of that.
The stock has a current market capitalization of $103.88M and its 3Y-monthly beta is at 1.15. It has posted earnings per share of -$0.06 in the same period. It has Quick Ratio of 10.15 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ZOM, volatility over the week remained 4.09% while standing at 2.15% over the month.
Stock’s fiscal year EPS is expected to drop by -37.14% while it is estimated to increase by 37.50% in next year. EPS is likely to shrink at an annualized rate of 8.29% for next 5-years, compared to annual growth of 27.70% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Dawson James on January 06, 2023 offering a Buy rating for the stock and assigned a target price of $6 to it.
